Blockade of osteopontin inhibits glomerular fibrosis in a model of anti-glomerular basement membrane glomerulonephritis

American Journal of Nephrology

Volumn 32, Issue 4, 2010, Pages 324-331

  Zhou, Cindy ^a   Wu, Jean ^a   Torres, Lisa ^a   Hicks, John M ^b   Bartkowiak, Todd ^a   Parker, Kiana ^a   Lou, Ya Huan ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Animal models; Extracellular matrix; Fibrosis; Glomerulonephritis

Indexed keywords

ANTISERUM; COLLAGEN; COLLAGEN 1ALPHA1; OSTEOPONTIN; OSTEOPONTIN ANTISERUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; GLOMERULAR FIBROSIS; GLOMERULONEPHRITIS; HISTOPATHOLOGY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; ANTIBODIES; FEMALE; FIBROSIS; FLOW CYTOMETRY; KIDNEY GLOMERULUS; MODELS, ANIMAL; OSTEOPONTIN; RATS; RATS, INBRED WKY;

EID: 77955608255     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319490     Document Type: Article

References (32)

1. Chatziantoniou C, Boffa JJ, Tharaux PL, Fla-mant M, Ronco P, Dussaule JC: Progression and regression in renal vascular and glomer-ular fibrosis. Int J Exp Pathol 2004; 85:1-11.
2. Eddy AA: Molecular basis of renal fibrosis. Pediatr Nephrol 2000; 15:290-301.
3. Strutz F, Zeisberg M: Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol 2006; 17:2992-2998.
4. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor p1. Nature 1990; 346: 371-374.
5. Gaedeke J, Peters H, Noble NA, Border WA: Angiotensin II, TGF-and Renal Fibrosis; in Wolf G (ed): The Renin-Angiotensin System and Progression of Renal Diseases. Contrib Nephrol. Basel, Karger, 2001, vol 135, pp 153-160.
6. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS: Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107:1055-1061.
7. Fogo AB: Renal fibrosis: not just PAI-1 in the sky. J Clin Invest 2003; 112:326-328.
8. O'Regan AW, Nau GJ, Chupp GL, Berman JS: Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 2000; 21:475-478.
9. Bird L: Asthma and allergy: opposing roles for osteopontin. Nature Rev Immunol 2007; 7:417.
10. Chabas D, Baranzini SE, Mitchell M, Bernard CCA, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L: The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294:1731-1735.
11. Pardo A, Gibson K, Cisneros J, Richards TJ, Ya ng Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M, Kaminski N: Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005; 2:e251.
12. Zahradka P: Novel role for osteopontin in cardiac fibrosis. Circ Res 2008; 102:270-272.
13. Mori R , Shaw TJ, Martin P: Molecular mechanisms linking wound in flammation and fi-brosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med 2008; 205:43-51.
14. Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R: Osteopontin expression is required for myofibroblast differentiation. Circ Res 2008; 102:319-327.
15. Xie Y, Sakatsume M, Nishi S, Narita I, Ara-kawa M, Gejyo F: Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 2001;60:1645-1657.
16. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J: Osteopon-tin-a molecule for all seasons. Q J Med 2002; 95:3-13.
17. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB: Osteopontin modulates angio-tensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009; 76:32-43.
18. Lan HY, Yu XQ, Yang N, Nikolic-Paterson DJ, Mu W, Pichler R, Johnson RJ, Atkins RC: De novo glomerular osteopontin expression in rat crescentic glomerulonephritis. Kidney Int 1998; 53 : 136-14 5 . (Pubitemid 28066913)
19. Yu XQ, Fan JM, Nikolic-Paterson DJ, Yang N, Mu W, Pichler R, Johnson RJ, Atkins RC, Lan HY: IL-1 up-regulates osteopontin expression in experimental crescentic glomer-ulonephritis in the rat. Am J Pathol 1999; 154: 833-841.
20. Yu XQ, Nikolic-Paterson DJ, Mu W, Giachel-li CM, Atkins RC, Johnson RJ, Lan HY: A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. Proc Assoc Am Phys 1998; 110:50-64. (Pubitemid 28051638)
21. Bonvini JM, Schatzmann U, Beck-Schimmer B, Sun LK, Rittling SR, Denhardt DT, Le Hir M, Wüthrich RP: Lack of in vivo function of osteopontin in experimental anti-GBM nephritis. J Am Soc Nephrol 2000; 11: 1647-1655.
22. Yoo KH, Thornhill BA, Forbes MS, Coleman CM, Marcinko ES, Liaw L, Chevalier RL: Os-teopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction. Kidney Int 2006; 70:1735-1741.
23. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB: Osteopontin modulates angio-tensin II induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009; 76:32-43.
24. Wu J, Hicks J, Borillo J, Glass WF 2nd, Lou YH: CD4+ T cells specific to a glomerular basement membrane antigen mediate glo-merulonephritis. J Clin Invest 2002; 10 9 :517-524.
25. Wu J, Hicks J, Borillo J, Glass WF 2nd, Lou YH: T cell epitope of glomerular basement membrane antigen induces severe glomerulonephritis. Kidney Int 2003; 64:1292-1301.
26. Merszei J, Wu J, Torres L, Hicks JM, Bart-kowiak T, Tan F, Lou YH: Osteopontin overproduction is associated with progression of glomerular fibrosis in a rat model of anti-GBM glomerulonephritis. Am J Nephrol (in press).
27. Alpers CE, Hudkins KL, Segerer S, Sage EH, Pichler R, Couser WG, Johnson RJ, Bassuk JA: Localization of SPARC in developing, mature, and chronically injured human allograft kidneys. Kidney Int 2002; 62: 2073-2086.
28. Wynn TA: Cellular and molecular mechanism of fibrosis. J Pathol 2008; 214: 199-210.
29. Xia H, Nho R, Kleidon J, Kahm J, Henke CA: Polymerized collagen inhibits fibroblasts proliferation via a mechanism involving the formation of a p1 integrin-protein phosphatase 2A-tuberous sclerosis complex 2complex that suppresses S6K1 activity. J Biol Chem 2008; 283:20350-20360.
30. Eckes B, Kessler D, Aumailly M, Krieg T: Interactions of fibroblasts with extracellular matrix: implications for the understanding of fibrosis. Springer Semin Immunopathol 2000; 21:415-429.
31. Chen Y, Bal BS, Gorsk JP: Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone. J Biol Chem 1992; 267: 24871-24878.
32. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL: Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998; 101:1468-1478.